Reblozyl
Phase 2Small molecule
Reblozyl is one of 43 small molecule programs targeting Anemia. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
272 competitors in Anemia
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 3
Feosol
AAuerbach Hematology Oncology Associates P C
Phase 3
Soliris
AstraZenecaPhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Vafseo
AAkebia Therapeutics
Phase 3
Omontys
TakedaPhase 3
Campath
GGenzyme, a Sanofi Company
Phase 3
Alkeran
AApotex Inc.
Phase 3
Jesduvroq
GGlaxo Dba Glaxosmithkline
Phase 3
Sodium Nitroprusside
WWatson Pharmaceuticals
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Reblozyl. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- EEuroBloodNet Association